Friedman BioVentures
VC Fund
Friedman BioVentures is a firm that invests in early-stage companies with promising technologies.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Friedman BioVentures invests in
Stages Friedman BioVentures invests in
Countries Friedman BioVentures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeffrey Friedman
|
|||
Investment Focus
Industry
- Biotechnology 5 (50%)
- Therapeutics 3 (30%)
- Pharmaceutical 3 (30%)
- Medical 2 (20%)
- Health Care 2 (20%)
Stage
- Seed 4 (40%)
- Series A 2 (20%)
- Series B 2 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jeffrey Friedman
Managing Partner
|
Managing Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Trio Pharmaceuticals
|
Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California. | $3.1M / Seed / Dec 03, 2024 | |
Hillhurst Biopharmaceuticals
|
Hillhurst has created technology that allows low-dose carbon monoxide to be used therapeutically (CO). Their medicines that arise target a protective cellular metabolic system of heme oxygenase, that is hypothesized to reduce inflammatory processes, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. Despite overwhelmingevidence of CO's potential efficacy as a therapy, it has not been commercially feasible to dose carbon monoxide. The methods of administration that have been tried, such as breathing CO and CO bound to a carrier like co releasing molecules/CORMS and CO prodrugs, have significant drawbacks. These hurdles for inhaled co include caregiver inhalation exposure due to the need for pressurized co gas cylinders and imprecise dosing. | Seed / Dec 20, 2023 | |
|
Trio Pharmaceuticals
|
Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California. | $2.2M / Seed / Mar 20, 2023 | |
PetDx
|
PetDx operates as a molecular diagnostics company dedicated to revolutionizing the detection and ultimately treatment of cancer for pets. Founded in 2019, PetDx is focused on the development of non-invasive tests with customized assays and next-generation sequencing-based techniques, thereby providing veterinarians with early detection,characterization, and management of cancer cells. | $62M / Series B / Dec 09, 2021 | |
DTx Pharma
|
DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake. | $100M / Series B / Mar 01, 2021 | |
Model Medicines
|
Model Medicines uses human expertise and AI to accelerate the development of life-changing drugs at scale. Model Medicines harnesses AI and ML with its ActivPred AI Drug Discovery Platform to discover drugs that may be repositioned to serve as therapeutics to treat patients suffering from humankind’s toughest diseases.The drugs that ModelMedicines discovers can enter clinical trials in as little as several months. | $4.1M / Seed / Feb 01, 2021 | |
|
PetDx
|
PetDx operates as a molecular diagnostics company dedicated to revolutionizing the detection and ultimately treatment of cancer for pets. Founded in 2019, PetDx is focused on the development of non-invasive tests with customized assays and next-generation sequencing-based techniques, thereby providing veterinarians with early detection,characterization, and management of cancer cells. | $10M / Series A / Jun 01, 2020 | |
|
DTx Pharma
|
DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake. | $10.6M / Series A / Jan 06, 2020 | |
|
DTx Pharma
|
DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake. | $3M / Series A / May 14, 2019 | |
MedCrypt
|
MedCrypt is a medical device company that provides data security as a service to medical device OEMs. From medical imaging device to implantable devices like pacemakers, MedCrypt ensures that devices act only on instructions from trusted sources. It brings security features to medical devices, from pacemakers to surgical robots, in a few lines ofcode. The company enables engineers to implement these security features properly as quickly as possible, allowing them to get back to designing life-changing clinical features.MedCrypt was founded in 2016 and is headquartered in Encinitas, California, United States. | $1.9M / Seed / Jun 28, 2018 |
Co-Investors
TCA Venture Group
4 deals together
Eli Lilly
2 deals together
ExSight Ventures
2 deals together
Nex Cubed
2 deals together
8VC
1 deal together
Access Biotechnology
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Friedman BioVentures invest in?
Friedman BioVentures invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Friedman BioVentures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Friedman BioVentures?
The team at Friedman BioVentures includes Jeffrey Friedman (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
